Multidrug resistance in brain tumors: roles of the blood-brain barrier
Malignant brain tumors and brain metastases present a formidable clinical challenge against which no significant advances have been made over the last decade. Multidrug resistance (MDR) is one of the main factors in the failure of chemotherapy against central nervous system tumors. The MDR1 gene enc...
Gespeichert in:
| Veröffentlicht in: | Cancer and metastasis reviews 2001-01, Vol.20 (1-2), p.13-25 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 25 |
|---|---|
| container_issue | 1-2 |
| container_start_page | 13 |
| container_title | Cancer and metastasis reviews |
| container_volume | 20 |
| creator | Régina, A Demeule, M Laplante, A Jodoin, J Dagenais, C Berthelet, F Moghrabi, A Béliveau, R |
| description | Malignant brain tumors and brain metastases present a formidable clinical challenge against which no significant advances have been made over the last decade. Multidrug resistance (MDR) is one of the main factors in the failure of chemotherapy against central nervous system tumors. The MDR1 gene encoding P-glycoprotein (P-gp), a drug efflux pump which plays a significant role in modulating MDR in a wide variety of human cancers, is highly expressed in the blood-brain barrier (BBB). The BBB controls central nervous system exposure to many endogenous and exogenous substances. The exact molecular mechanisms by which the BBB is involved in the resistance of brain tumors to chemotherapy remain to be identified. The purpose of this review is to summarize reports demonstrating that P-gp, one of the most phenotypically important markers of the BBB, is present in primary brain tumors and thus plays a crucial role in their clinical resistance to chemotherapy. |
| doi_str_mv | 10.1023/A:1013104423154 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72428041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>358017921</sourcerecordid><originalsourceid>FETCH-LOGICAL-p261t-e39ee9f0c7d974f1a35f7e2bbd0662bc0eecff83e9391ea4f9c7ee7b2b7912fd3</originalsourceid><addsrcrecordid>eNqF0DFPwzAQBWALgWgpzGwoYmAL-HxOXHerKgpIRSwwR3ZyhlRJXOxk4N8T1LKwsLy3fDqdHmOXwG-BC7xbLoADApdSIGTyiE0hU5gqgXjMphxylao80xN2FuOWc65Q6VM2AZgj5BKmbP08NH1dheE9CRTr2JuupKTuEhvMmP3Q-hAXSfANxcS7pP-gxDbeV-keWBNCTeGcnTjTRLo49Iy9re9fV4_p5uXhabXcpDuRQ58SaiLteKkqraQDg5lTJKyteJ4LW3Ki0rk5kkYNZKTTpSJSVlilQbgKZ-xmf3cX_OdAsS_aOpbUNKYjP8RCCSnmXMIIr__ArR9CN_5WCJAo9c9E_6EMVDaiqwMabEtVsQt1a8JX8bshfgNAinKN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214349723</pqid></control><display><type>article</type><title>Multidrug resistance in brain tumors: roles of the blood-brain barrier</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Régina, A ; Demeule, M ; Laplante, A ; Jodoin, J ; Dagenais, C ; Berthelet, F ; Moghrabi, A ; Béliveau, R</creator><creatorcontrib>Régina, A ; Demeule, M ; Laplante, A ; Jodoin, J ; Dagenais, C ; Berthelet, F ; Moghrabi, A ; Béliveau, R</creatorcontrib><description>Malignant brain tumors and brain metastases present a formidable clinical challenge against which no significant advances have been made over the last decade. Multidrug resistance (MDR) is one of the main factors in the failure of chemotherapy against central nervous system tumors. The MDR1 gene encoding P-glycoprotein (P-gp), a drug efflux pump which plays a significant role in modulating MDR in a wide variety of human cancers, is highly expressed in the blood-brain barrier (BBB). The BBB controls central nervous system exposure to many endogenous and exogenous substances. The exact molecular mechanisms by which the BBB is involved in the resistance of brain tumors to chemotherapy remain to be identified. The purpose of this review is to summarize reports demonstrating that P-gp, one of the most phenotypically important markers of the BBB, is present in primary brain tumors and thus plays a crucial role in their clinical resistance to chemotherapy.</description><identifier>ISSN: 0167-7659</identifier><identifier>EISSN: 1573-7233</identifier><identifier>DOI: 10.1023/A:1013104423154</identifier><identifier>PMID: 11831641</identifier><identifier>CODEN: CMRED4</identifier><language>eng</language><publisher>Netherlands: Springer Nature B.V</publisher><subject>Antineoplastic Agents - therapeutic use ; ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism ; Blood-Brain Barrier ; Brain cancer ; Brain Neoplasms - drug therapy ; Brain Neoplasms - metabolism ; Chemotherapy ; Drug resistance ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Humans ; Multidrug Resistance-Associated Proteins - metabolism ; Treatment</subject><ispartof>Cancer and metastasis reviews, 2001-01, Vol.20 (1-2), p.13-25</ispartof><rights>Copyright Kluwer Academic Publishers 2001</rights><rights>Copyright Kluwer Academic Publishers Mar-Jun 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11831641$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Régina, A</creatorcontrib><creatorcontrib>Demeule, M</creatorcontrib><creatorcontrib>Laplante, A</creatorcontrib><creatorcontrib>Jodoin, J</creatorcontrib><creatorcontrib>Dagenais, C</creatorcontrib><creatorcontrib>Berthelet, F</creatorcontrib><creatorcontrib>Moghrabi, A</creatorcontrib><creatorcontrib>Béliveau, R</creatorcontrib><title>Multidrug resistance in brain tumors: roles of the blood-brain barrier</title><title>Cancer and metastasis reviews</title><addtitle>Cancer Metastasis Rev</addtitle><description>Malignant brain tumors and brain metastases present a formidable clinical challenge against which no significant advances have been made over the last decade. Multidrug resistance (MDR) is one of the main factors in the failure of chemotherapy against central nervous system tumors. The MDR1 gene encoding P-glycoprotein (P-gp), a drug efflux pump which plays a significant role in modulating MDR in a wide variety of human cancers, is highly expressed in the blood-brain barrier (BBB). The BBB controls central nervous system exposure to many endogenous and exogenous substances. The exact molecular mechanisms by which the BBB is involved in the resistance of brain tumors to chemotherapy remain to be identified. The purpose of this review is to summarize reports demonstrating that P-gp, one of the most phenotypically important markers of the BBB, is present in primary brain tumors and thus plays a crucial role in their clinical resistance to chemotherapy.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism</subject><subject>Blood-Brain Barrier</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - metabolism</subject><subject>Chemotherapy</subject><subject>Drug resistance</subject><subject>Drug Resistance, Multiple</subject><subject>Drug Resistance, Neoplasm</subject><subject>Humans</subject><subject>Multidrug Resistance-Associated Proteins - metabolism</subject><subject>Treatment</subject><issn>0167-7659</issn><issn>1573-7233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqF0DFPwzAQBWALgWgpzGwoYmAL-HxOXHerKgpIRSwwR3ZyhlRJXOxk4N8T1LKwsLy3fDqdHmOXwG-BC7xbLoADApdSIGTyiE0hU5gqgXjMphxylao80xN2FuOWc65Q6VM2AZgj5BKmbP08NH1dheE9CRTr2JuupKTuEhvMmP3Q-hAXSfANxcS7pP-gxDbeV-keWBNCTeGcnTjTRLo49Iy9re9fV4_p5uXhabXcpDuRQ58SaiLteKkqraQDg5lTJKyteJ4LW3Ki0rk5kkYNZKTTpSJSVlilQbgKZ-xmf3cX_OdAsS_aOpbUNKYjP8RCCSnmXMIIr__ArR9CN_5WCJAo9c9E_6EMVDaiqwMabEtVsQt1a8JX8bshfgNAinKN</recordid><startdate>20010101</startdate><enddate>20010101</enddate><creator>Régina, A</creator><creator>Demeule, M</creator><creator>Laplante, A</creator><creator>Jodoin, J</creator><creator>Dagenais, C</creator><creator>Berthelet, F</creator><creator>Moghrabi, A</creator><creator>Béliveau, R</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>M0S</scope><scope>M1P</scope><scope>M3G</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20010101</creationdate><title>Multidrug resistance in brain tumors: roles of the blood-brain barrier</title><author>Régina, A ; Demeule, M ; Laplante, A ; Jodoin, J ; Dagenais, C ; Berthelet, F ; Moghrabi, A ; Béliveau, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p261t-e39ee9f0c7d974f1a35f7e2bbd0662bc0eecff83e9391ea4f9c7ee7b2b7912fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism</topic><topic>Blood-Brain Barrier</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - metabolism</topic><topic>Chemotherapy</topic><topic>Drug resistance</topic><topic>Drug Resistance, Multiple</topic><topic>Drug Resistance, Neoplasm</topic><topic>Humans</topic><topic>Multidrug Resistance-Associated Proteins - metabolism</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Régina, A</creatorcontrib><creatorcontrib>Demeule, M</creatorcontrib><creatorcontrib>Laplante, A</creatorcontrib><creatorcontrib>Jodoin, J</creatorcontrib><creatorcontrib>Dagenais, C</creatorcontrib><creatorcontrib>Berthelet, F</creatorcontrib><creatorcontrib>Moghrabi, A</creatorcontrib><creatorcontrib>Béliveau, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>CBCA Reference & Current Events</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer and metastasis reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Régina, A</au><au>Demeule, M</au><au>Laplante, A</au><au>Jodoin, J</au><au>Dagenais, C</au><au>Berthelet, F</au><au>Moghrabi, A</au><au>Béliveau, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multidrug resistance in brain tumors: roles of the blood-brain barrier</atitle><jtitle>Cancer and metastasis reviews</jtitle><addtitle>Cancer Metastasis Rev</addtitle><date>2001-01-01</date><risdate>2001</risdate><volume>20</volume><issue>1-2</issue><spage>13</spage><epage>25</epage><pages>13-25</pages><issn>0167-7659</issn><eissn>1573-7233</eissn><coden>CMRED4</coden><abstract>Malignant brain tumors and brain metastases present a formidable clinical challenge against which no significant advances have been made over the last decade. Multidrug resistance (MDR) is one of the main factors in the failure of chemotherapy against central nervous system tumors. The MDR1 gene encoding P-glycoprotein (P-gp), a drug efflux pump which plays a significant role in modulating MDR in a wide variety of human cancers, is highly expressed in the blood-brain barrier (BBB). The BBB controls central nervous system exposure to many endogenous and exogenous substances. The exact molecular mechanisms by which the BBB is involved in the resistance of brain tumors to chemotherapy remain to be identified. The purpose of this review is to summarize reports demonstrating that P-gp, one of the most phenotypically important markers of the BBB, is present in primary brain tumors and thus plays a crucial role in their clinical resistance to chemotherapy.</abstract><cop>Netherlands</cop><pub>Springer Nature B.V</pub><pmid>11831641</pmid><doi>10.1023/A:1013104423154</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-7659 |
| ispartof | Cancer and metastasis reviews, 2001-01, Vol.20 (1-2), p.13-25 |
| issn | 0167-7659 1573-7233 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72428041 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic Agents - therapeutic use ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism Blood-Brain Barrier Brain cancer Brain Neoplasms - drug therapy Brain Neoplasms - metabolism Chemotherapy Drug resistance Drug Resistance, Multiple Drug Resistance, Neoplasm Humans Multidrug Resistance-Associated Proteins - metabolism Treatment |
| title | Multidrug resistance in brain tumors: roles of the blood-brain barrier |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A07%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multidrug%20resistance%20in%20brain%20tumors:%20roles%20of%20the%20blood-brain%20barrier&rft.jtitle=Cancer%20and%20metastasis%20reviews&rft.au=R%C3%A9gina,%20A&rft.date=2001-01-01&rft.volume=20&rft.issue=1-2&rft.spage=13&rft.epage=25&rft.pages=13-25&rft.issn=0167-7659&rft.eissn=1573-7233&rft.coden=CMRED4&rft_id=info:doi/10.1023/A:1013104423154&rft_dat=%3Cproquest_pubme%3E358017921%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214349723&rft_id=info:pmid/11831641&rfr_iscdi=true |